Molbio Diagnostics IPO Review 2026: Business, Financials and Key Considerations
Molbio Diagnostics Limited, a Goa-headquartered point-of-care (POC) molecular diagnostics company, is opening its ₹939.70 crore initial public offering on August 10, 2026. The company has developed the a platform — a portable, battery-operated PCR-based testing system used to diagnose infectious diseases like tuberculosis, COVID-19, HIV, and hepatitis in under an hour, without needing a centralized lab. This review covers the offer structure, GMP, financials, business model, and the strengths and risks disclosed in the offer documents, so you can form your own view before the issue closes on August 12, 2026.
Molbio Diagnostics IPO: Quick Overview
Key issue details, price band, lot size and important dates
| Detail | Value |
|---|---|
| Issue Size | ₹939.70 crore |
| Fresh Issue |
24,80,246 shares Approximately ₹200.00 crore |
| Offer for Sale |
91,66,000 shares Approximately ₹739.70 crore |
| Price Band | ₹768 – ₹807 per equity share |
| Face Value | ₹1 per equity share |
| Lot Size | 18 shares |
| Minimum Retail Investment | ₹14,526 |
| IPO Open Date | |
| IPO Close Date |
KFin Technologies Limited is the registrar for the IPO and will manage allotment, refunds, and other investor-related processes. Kotak Mahindra Capital Company Limited, IIFL Capital Services Limited, Jefferies India Private Limited, and Motilal Oswal Investment Advisors Limited are the lead managers responsible for overseeing the issue and coordinating the overall IPO process. You can track live updates on the Molbio Diagnostics IPO detail page on IPO Ji. The Red Herring Prospectus was filed with SEBI on August 3, 2026.
About Molbio Diagnostics
Molbio Diagnostics Limited is a point-of-care molecular diagnostics company known for its portable PCR-based a platform, which enables rapid testing for 30 diseases in under an hour.
The company also provides radiology, digital pathology, and breast health screening solutions. It operates manufacturing facilities in India and serves over 90 countries through 33 international distributors.
Molbio earns revenue from diagnostic equipment sales and recurring demand for proprietary test kits.
Financial Performance of Molbio Diagnostics
Figures below are drawn from the company's restated financials as reflected on the current offer page, in ₹ crore.
- Total Income grew from ₹840.66 Cr in FY24, to ₹1,027.94 Cr in FY25, to ₹1,455.17 Cr in FY26.
- Profit After Tax rose each year — ₹83.54 Cr (FY24), ₹138.58 Cr (FY25), ₹164.14 Cr (FY26).
- Net Worth increased from ₹807.94 Cr (FY24) to ₹952.95 Cr (FY25) to ₹1,144.68 Cr (FY26).
- Reserves & Surplus rose from ₹845.48 Cr (FY24) to ₹990.84 Cr (FY25) to ₹1,148.84 Cr (FY26).
- Total Assets grew from ₹1,221.06 Cr (FY24) to ₹1,461.56 Cr (FY25) to ₹2,148.42 Cr (FY26).
- Total Borrowings moved from ₹174.58 Cr (FY24) down to ₹123.16 Cr (FY25), then up sharply to ₹412.64 Cr (FY26) — worth noting as a non-linear trend rather than steady movement, and worth understanding against the company's FY26 asset growth before forming a view.
Strengths of Molbio Diagnostics
- Strong position in molecular diagnostics. The company is favorably placed to benefit from the emerging molecular diagnostics market on the back of its a point-of-care platform.
- Innovation & R&D capability. A track record of developing and commercializing innovative diagnostic products underpins the company's research and development capacity.
- Proprietary point-of-care platform. Molbio has developed and commercialized its own a point-of-care molecular diagnostics platform, built on PCR technology.
Risks of Molbio Diagnostics
- R&D and regulatory approval risk. The company's growth depends on effective research and development, and on securing regulatory approval for new diagnostic tests.
- Variable sales demand. A variable sales cycle makes it difficult to predict revenues and overall business performance.
- Demand forecasting and stock management risk. An inability to accurately forecast demand and manage inventories could result in excess inventory or shortages.
These risks are drawn directly from the offer documents' disclosures and aren't exhaustive — anyone evaluating this IPO should read the full "Risk Factors" section of the Red Herring Prospectus before forming a view.
How to Apply for Molbio Diagnostics IPO
You can apply for the Molbio Diagnostics IPO through the IPO Ji app, your broker's app, or via net banking using ASBA. The typical steps are:
- Log in to your broker or banking app's IPO section.
- Select "Molbio Diagnostics IPO" from the list of open issues.
- Enter your UPI ID, choose your bid quantity (in multiples of the 18-share lot), and select your price within the band.
- Submit the application and approve the UPI mandate request when it arrives.
Once allotment is finalized on August 13, 2026, you can check your status on the Molbio Diagnostics IPO allotment status page.
Frequently Asked Questions
Key questions about the Molbio Diagnostics IPO
What is Molbio Diagnostics IPO?
Molbio Diagnostics IPO is a book-built mainboard issue worth ₹939.70 crore, priced at ₹768–₹807 per share. It opens on August 10, 2026 and closes on August 12, 2026, and is expected to list on the BSE and NSE.
What is the price band for Molbio Diagnostics IPO?
The price band is ₹768 to ₹807 per equity share, with a face value of ₹1 per share.
What is the lot size for Molbio Diagnostics IPO?
The lot size is 18 shares. Retail investors can bid for a minimum of one lot and a maximum of 13 lots, or 234 shares.
What is the minimum investment required?
The minimum retail investment is approximately ₹14,526, based on the upper end of the price band.
When does Molbio Diagnostics IPO open and close?
The IPO opens on August 10, 2026 and closes on August 12, 2026. The anchor investor bidding date is August 7, 2026.
When is the Molbio Diagnostics IPO allotment date?
The allotment is expected to be finalized on August 13, 2026.
When will Molbio Diagnostics shares list?
Molbio Diagnostics is expected to list on August 17, 2026 on both the BSE and NSE.
Is Molbio Diagnostics IPO a fresh issue or an offer for sale?
It includes both. The IPO comprises a fresh issue of 24,80,246 shares, worth approximately ₹200 crore, and an offer for sale of 91,66,000 shares, worth approximately ₹739.70 crore.
What is the GMP of Molbio Diagnostics IPO?
Check the latest and day-wise Molbio Diagnostics IPO GMP observations on IPO Ji.
What is the valuation of Molbio Diagnostics IPO?
Based on the RHP financials and price band, the IPO has an approximate post-issue EPS of ₹14.24, a post-issue P/E of approximately 56.67, and a Return on Net Worth of 14.55%.
The post-issue market capitalisation at the upper price band is approximately ₹9,299.87 crore. These figures are computed estimates and should be treated accordingly.
How will the fresh issue proceeds be used?
The fresh issue proceeds are intended to fund capital expenditure for the company’s R&D facility, Center of Excellence, connected office space, and plant, machinery and equipment at its Goa and Visakhapatnam facilities. A portion will also be used for general corporate purposes.
What does Molbio Diagnostics do?
Molbio Diagnostics is a point-of-care molecular diagnostics company. Its proprietary a platform provides decentralized PCR-based testing for over 30 diseases, including TB, COVID-19, HIV and hepatitis, in under an hour.
The company also offers radiology, digital pathology and breast health screening solutions through its subsidiaries and collaborations.
Who are the promoters of Molbio Diagnostics?
The promoters are Sriram Natarajan, Dr. Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.
Where can I check the live subscription status?
You can track live subscription figures across the retail, NII and QIB categories on the Molbio Diagnostics IPO subscription status page on IPO Ji or through the stock exchange websites.
Read more
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs. All matter published here is purely for educational and information purposes only. We are not a SEBI registered analyst. Readers must consult a qualified financial advisor before making investment decisions.
